Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
Fulvestrant maintenance therapy significantly improves progression free survival compared to capecitabine in hormone receptor positive metastatic breast cancer patients
This randomized phase 3 trial in 210 patients with HR+ HER2- metastatic breast cancer compared fulvestrant to capecitabine after first-line …
In a study of 210 patients in China, fulvestrant helped keep cancer from growing longer than capecitabine. Fewer serious side effects occurr…
Unplanned Healthcare Encounters Common in Pediatric Cancer
Pain and nausea drive unplanned visits in pediatric cancer
In 444 pediatric cancer patients, 652 unplanned encounters occurred over 8 weeks. Pain and nausea/vomiting were frequent reasons.
Pain and nausea are top reasons kids with cancer end up in the ER or hospital, a new analysis finds.
Systematic review and meta-analysis on neoadjuvant chemoimmunotherapy for resectable NSCLC
Doctors found that certain cancer cells after treatment linked to lower survival chances for lung patients
This systematic review and meta-analysis synthesized evidence on neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer. I…
A review of studies shows that having cancer cells in lymph nodes after surgery makes lung cancer harder to treat. Patients with these cells…
Case report on VMAT radiotherapy for inoperable anal Buschke-Lowenstein tumors
Radiotherapy offers hope for rare anal tumors in two patients
This case report with literature review describes two patients with inoperable anal Buschke-Lowenstein tumors treated with definitive radiot…
Two patients with inoperable anal tumors showed clinical improvement after receiving definitive radiotherapy, suggesting a viable option for…
Systematic review and meta-analysis links benzene exposure to increased lymphoid neoplasm risk
Benzene exposure linked to higher lymphoid neoplasm risk in large review
This systematic review and meta-analysis evaluated 95 human studies on benzene exposure across occupational and environmental settings. The …
A review of 95 studies shows benzene exposure is associated with a significantly higher risk of lymphoid neoplasms, including Hodgkin lympho…
Review of AI models shows high accuracy for ovarian cancer diagnosis and outcome prediction
Artificial intelligence models outperform traditional methods for ovarian cancer diagnosis
This review synthesizes evidence on artificial intelligence and machine learning models for ovarian cancer. The authors note these tools dem…
A review found AI models showed high accuracy in diagnosing ovarian cancer and predicting patient outcomes, potentially improving care.
FDA Approves Herceptin (trastuzumab) for HER2-Overexpressing Breast and Gastric Cancers
FDA approves Herceptin for certain breast and stomach cancers.
The FDA approved Herceptin (trastuzumab) for the treatment of HER2-overexpressing breast cancer (adjuvant and metastatic) and HER2-overexpre…
The FDA approved Herceptin (trastuzumab) for HER2-positive breast cancer and stomach cancer. It targets tumors with high levels of HER2 prot…
FDA Approves Phesgo (pertuzumab, trastuzumab, hyaluronidase) for HER2-Positive Breast Cancer
FDA approves new shot for HER2 positive breast cancer treatment
The FDA approved Phesgo, a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase for subcutaneous injection, for HER2-positiv…
The FDA approved Phesgo, a new shot for HER2 positive breast cancer. It treats early and metastatic breast cancer. This gives patients a fas…
FDA Approves Herceptin Hylecta (trastuzumab/hyaluronidase) for HER2+ Breast Cancer
FDA approves new shot for HER2 positive breast cancer treatment
FDA approved Herceptin Hylecta, a subcutaneous formulation of trastuzumab with hyaluronidase, for adjuvant and metastatic HER2-overexpressin…
The FDA approved Herceptin Hylecta, a shot for HER2 positive breast cancer. It is given under the skin in minutes instead of an IV drip. Thi…
Systematic Review Maps Exponential Growth of Antibody-Drug Conjugate Trials in Lung Cancer
Global review shows antibody-drug conjugates for lung cancer trials are growing fast
This systematic review of 466 global trials documents exponential growth in antibody-drug conjugate (ADC) trials for lung cancer, from 1 in …
A global review of lung cancer trials shows antibody-drug conjugate research is expanding rapidly, with more than 100 new trials registered …
Meta-analysis links emotional distress to worse outcomes in advanced lung cancer
Emotional distress linked to worse lung cancer survival
This systematic review and meta-analysis of 911 patients with advanced NSCLC found emotional distress was significantly associated with redu…
For people with advanced lung cancer, feeling emotionally distressed is tied to lower survival and worse treatment response, a new analysis …
Meta-analysis shows bevacizumab plus FOLFOX improves response rates without increasing common toxicities in advanced colorectal cancer
Adding bevacizumab to standard chemo improves tumor response in advanced colorectal cancer
This systematic review and meta-analysis evaluated bevacizumab combined with FOLFOX versus FOLFOX alone in patients with advanced or metasta…
A large review found that adding bevacizumab to standard chemotherapy improves how well tumors respond and keeps disease under control longe…